Orellanine for kidney cancer patients on dialysis
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-stage study tests orellanine to treat advanced kidney cancer that has spread (metastatic clear-cell or papillary type). It may help by shrinking or controlling cancer, and by seeing whether the treatment is safe and tolerable in people already on chronic dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have advanced clear-cell or papillary kidney cancer confirmed by pathology (biopsy or surgery).
- Do not have a standard treatment option available or your doctor and you decided against conventional therapy.
- Be an adult (18+) and able to travel for study visits and testing.
- Be on long-term hemodialysis, with the same dialysis schedule for the last 3 months.
- Have blood counts and liver blood tests in acceptable ranges (specific lab cutoffs) and a life expectancy of at least 3 months.
- Not be pregnant or breastfeeding, and use 2 reliable contraception methods during the study and for a few months after the last dose.
- Be well enough functionally (ECOG 0–2) and have recovered from prior treatment side effects to at least mild levels (except hair loss and some nerve issues).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
Hear when a new Carcinoma, Renal Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.